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Abstract
Background: Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene. The immune
inflammatory response also contributes to disease progression in DMD patients. In a previous study, we
demonstrated higher levels of circulating CD49dhi and CD49ehi T cells in DMD patients compared to healthy
control. DMD patients are clinically heterogeneous and the functional defect cannot be correlated with genotype.
Therefore, it is important to be able to define reliable noninvasive biomarkers to better define the disease
progression at the beginning of clinical trials.
Results: We studied 75 DMD patients at different stages of their disease and observed that increased percentages
of circulating CD4+CD49dhi and CD8+CD49dhi T lymphocytes were correlated with both severity and a more rapid
progression of the disease. Moreover, T+CD49d+ cells were also found in muscular inflammatory infiltrates.
Functionally, T cells from severely affected patients exhibited higher transendothelial and fibronectin-driven
migratory responses and increased adhesion to myotubes, when compared to control individuals. These responses
could be blocked with an anti-CD49d monoclonal antibody.
Conclusion: CD49d can be used as a novel biomarker to stratify DMD patients by predicting disease progression
for clinical trials. Moreover, anti-CD49d peptides or antibodies can be used as a therapeutic approach to decrease
inflammation-mediated tissue damage in DMD.
Keywords: Duchenne muscular dystrophy, Inflammation, CD49d, T lymphocytes, Predictive biomarker,
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Background
Duchenne muscular dystrophy (DMD) is the most
common genetic muscular dystrophy, affecting 1 in
5000 male births. It is caused by mutations in the
dystrophin gene, leading to functional loss or absence
of the protein [1, 2]. The results of a recent phase 3
clinical trial using exon-skipping strategies failed to
show significant functional improvement [3, 4] prob-
ably due to the clinical heterogeneity of the patients
that is a hallmark of the disease [5]. This emphasizes
the urgent need to define reliable noninvasive bio-
markers to better define these patient populations at
the beginning of the trial and monitor the results of
corrective strategies.
It is known that in DMD, there is an inflammatory
process following muscular necrosis, which leads to fi-
brotic remodeling [6]. In this context, it has been
* Correspondence: gillian.butler-browne@upmc.fr; savino.w@gmail.com
Suse Dayse Silva-Barbosa, Gillian Butler-Browne, and Wilson Savino share the
seniorship of the manuscript.
3Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, CNRS
FRE3617, Center for Research in Myology, 47 boulevard de l’Hopital, Paris
75651, France
1Laboratory on Thymus Research, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Full list of author information is available at the end of the article
© 2015 Pinto-Mariz et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pinto-Mariz et al. Skeletal Muscle  (2015) 5:45 
DOI 10.1186/s13395-015-0066-2
demonstrated that there is a correlation between the ab-
sence of B and T lymphocytes and a decrease in fibrosis
in the SCID/mdx mouse [7]. Fibrogenetic growth factors
and their receptors are upregulated and localized with
inflammatory cells in muscles of DMD patients [8].
More recently, it has been demonstrated that osteopon-
tin, the ligand for the integrin VLA-4, is upregulated in
the muscle fibers and inflammatory infiltrates in DMD
patients, suggesting that it is involved in both fibrosis
and inflammation [9]. A dysregulation in extracellular
matrix (ECM) expression has also been demonstrated in
DMD patients [10–12], together with increased expres-
sion of ECM receptors on inflammatory cells near re-
gions of necrosis in the mdx model [13]. These data
suggest that ECM-mediated cell interactions contribute
to the migration of cells to the site of muscle damage,
triggering and maintaining local inflammation and
fibrosis.
We previously found that DMD patients exhibited
higher relative numbers of CD4+ and CD8+ T cells
expressing higher levels of the alpha-4 chain of the
integrin VLA-4 (CD49dhi) and alpha-5 chain of the
integrin VLA-5 (CD49ehi), both of which are fibro-
nectin receptors [14]. In the present study, we investi-
gated if those subpopulations are correlated with
disease severity and disease progression in DMD pa-
tients. We demonstrate that CD49d can be used as a
biomarker to monitor both severity and progression
of disease in DMD patients. In addition, ex vivo cell
migration experiments strongly suggest that CD49d
participates to the migration of inflammatory cells
into the muscle.
To our knowledge, this is the first study that pro-
poses a reliable circulating biomarker that can be
used to stratify DMD patients into homogeneous
groups thereby improving the power of significance of
results of clinical trials. Finally, these results suggest
that in addition CD49d could be used as a thera-




We enrolled 75 patients from the Pediatrics Institute,
Federal University of Rio de Janeiro (IPPMG/UFRJ),
Brazil (Additional file 1: Table S1), for whom the gen-
etic and/or histological diagnosis of DMD had been
confirmed. They were divided into three groups ac-
cording to their ability to walk: 10 m in less than
10 s (speed > 1 m/s; n = 19), 10 m in 10 s or more
(speed ≤ 1 m/s; n = 25), and unable to walk (n = 31).
These groups were further subdivided according to
the age at which they had stopped walking: before or
after 10 years of age (rapid progression, n = 16, and
slow progression, n = 15, respectively). A control
group (n = 14) comprised age-/sex-matched healthy
volunteers.
We also developed a prospective study of CD49d
levels on T cells in DMD patients who were able to walk
at a speed ≤1 m/s and were followed until they lost their
ability to walk. If such a loss occurred before 10 years of
age, this was considered rapid progression, whereas after
10 years of age, it was considered slow progression.
We also evaluated biopsies from DMD patients who
had lost ambulation before (n = 4) or after (n = 5)
10 years of age. The biopsies were obtained at the be-
ginning of the disease as part of the diagnostic pro-
cedure, at Necker Children’s Hospital, Paris, France
(Additional file 2: Table S2). As controls, we used
three age-/gender-matched muscle samples from chil-
dren undergoing orthopedic surgery for non-muscle-
related reasons.
Twenty-two IBM patients were enrolled for a natural
history study of IBM, and their diagnosis and clinical
characteristics are described [15]. Peripheral blood
mononuclear cells (PBMCs) of IBM patients were com-
pared to healthy subjects (n = 22), who were matched for
sex and age, free of inflammatory/autoimmune diseases,
past history of cancer or active cancer, and were not re-
ceiving any immunosuppressive or immunomodulatory
drug. The institutional review board approved the study
protocol, also for ancillary studies on their blood sam-
ples [16].
Procedures have been approved by the ethical commit-
tees of the IPPMG/UFRJ (Research and Ethical Commit-
tee of IPPMG/UFRJ—Comitê de Ética e Pesquisa do
Instituto de Puericultura e Pediatria Martagão Gesteira/
Universidade Federal do Rio de Janeiro; reference num-
ber 06/06), CPP Ile de France (reference number
14.323), and the Ministère de la Recherche and Cochin
Hospital Cell Bank, Paris, agreement number DC-2009-
944. All the patients and/or parents gave written individ-
ual informed consent to participate in the study.
In situ immunofluorescence and cytofluorometry
General features of antibodies are presented in Add-
itional file 3, Table S3. Sequential gating of cells for
CD49d evaluation is illustrated in Additional file 4,
Figure S1. For cytofluorometry, we used fluorochrome-
labeled monoclonal antibodies with specificities for CD3,
CD4, CD8, CD11a, CD14, CD19, CD49a, CD49d,
CD49e, or CD49f. Isotype-/fluorochrome-matched unre-
lated antibodies were also Pharmingen reagents. Flow
cytometry assays were carried out as described previ-
ously [14]. To characterize the inflammatory infiltrate in
the muscle biopsies, we used anti-CD3, anti-CD4, anti-
CD8, anti-CD49d, and anti-HLA-DR monoclonal anti-
bodies (mAb). Nuclei were visualized using DAPI
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(Sigma-Aldrich, St. Louis, USA). Secondary goat anti-
mouse or goat anti-rabbit antibodies conjugated to fluo-
rochromes (Alexa Fluor 594, Alexa Fluor 488, Streptavi-
din Cy5—in the case of biotinylated secondary antibody)
were used to reveal primary antibodies.
In situ immunofluorescence analyses were made on
frozen sections of muscle biopsies as described [17]. We
performed immunostaining for simultaneous detection
of CD3, CD4, or CD8; HLA-DR; and CD49d. In each
muscle biopsy, all the inflammatory fields were recorded.
We have also performed experiments with isotype-
matched unrelated reagents in the same muscle samples
obtained from DMD and healthy control subjects: no
background staining was observed. We performed
immunostainings in samples from patients with IBM
and polymyositis, and the staining patterns for CD3,
CD4, and CD8 matched those described in the
literature.
Images were analyzed with Metamorph software (Mo-
lecular Devices, Toronto, Canada). The absolute num-
bers of CD8+ and CD4+ cells in situ were determined in
all inflammatory fields, defined by the presence of cell
clusters identified with DAPI nuclear staining.
Cell migration assays
The migratory responses of T lymphocytes through fi-
bronectin or endothelial cells were measured using 5-
μm pore size Transwell chambers (Costar; Corning). For
fibronectin-driven migration, the insert membranes were
coated and blocked as described [17]. For transendothe-
lial cell migration, 105 human umbilical vein endothelial
cells (Promo Cell, Heidelberg, Germany) were added
onto the insert membranes of transwell plates. After
24 h, the cultures were confluent and the inserts were
washed with RPMI-1640. In both assays, 106 PBMCs
were placed in the upper chamber and left to migrate
for 16 h. Migrating cells were phenotyped by flow cy-
tometry. For the blocking assay, 106 cells were pretreated
for 10 min with 10 μl of purified anti-CD49d mAb and
migrated as described above. In the case of blockage of
adhesion by specific antibodies, data are presented as a
percentage of the migration values obtained following
pretreatment with unrelated antibodies, applied on cells
from the same subject. In cell migration experiments,
data was normalized to measure the percentage of input,
using the following formula:
% input ¼ ð numberof migratingcellsof agivenphenotype 100Þ
totalnumberof cellsof agivenphenotypeallowedtomigrate
Lymphocyte adhesion to myotubes
Human myoblasts were cultured in Ham’s F-10 medium
[18]. Differentiation was induced as described [19]. One
million PBMCs from healthy individuals or DMD pa-
tients were allowed to adhere onto myotubes for 2 h at
37 °C and washed to remove non-adherent PBMCs. Ad-
herent cells were counted and phenotyped. Unrelated
IgG1 or anti-CD49d mAb (1 μg/ml) was added in PBMC
suspensions before co-culturing with myotubes. In the
case of adhesion blockage by specific antibodies, data
are presented as percentages of the values obtained with
unrelated antibodies, applied on cells from the same
subject.
Statistics
For continuous data, groups were compared by the
Mann-Whitney test (for two groups) or Kruskal-Wallis
test followed by Dunn’s multiple comparison test (for
more than two groups). Statistical analyses were per-
formed using GraphPad Prism software version 5 for
Windows. Differences were considered statistically sig-
nificant when p values were ≤0.05.
Results
High numbers of CD49dhi T cells are correlated with
disease progression
We first evaluated the membrane expression levels of
various integrin α subunits on circulating T cells,
comparing a large cohort of DMD patients with
healthy individuals (Table 1). We found higher rela-
tive numbers of CD49dhiCD4+ (p = 0.007) and CD8+
T lymphocytes (p = 0.009) in DMD patients, although
they exhibited similar numbers of CD4+ or CD8+ T
cells/mm in the blood compared to controls. This
was specific to T cell subsets, since CD49d expression
levels were similar in CD19+ B lymphocytes and
CD14+ monocytes, when comparing healthy and
DMD subjects (Additional file 5: Figure S2).
When DMD patients were split into different sub-
groups, able to walk relatively fast (more than 1 m/s),
still able to walk but more severely affected (1 m/s or
less), and those who were no longer able to walk, the
relative numbers of CD49dhiCD4+ and CD49dhiCD8+ T
cells were significantly higher in the more severe DMD
patients, as compared to the groups ≤1 m/s and unable
to walk (Fig. 1a, b). No significant difference was ob-
served between patients that could walk faster than 1 m/
s with healthy controls.
In a retrospective study of wheelchair-bound DMD pa-
tients, we observed higher percentages of CD49dhiCD4+
and CD49dhiCD8+ T cells in patients who had lost am-
bulation before 10 years of age (rapid disease progres-
sion), compared to those who had become wheelchair
bound at or after 10 years of age (slow disease progres-
sion) (Fig. 1c). These findings clearly indicate that higher
numbers of CD49dhi T cells correlate with rapid disease
progression.
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In a prospective study of 23 DMD patients followed
until loss of ambulation, we found that a significantly
higher number of CD49dhiCD4+ and CD49dhiCD8+ T
cells were observed at the beginning of the study in the
group of patients who subsequently lost ambulation be-
fore 10 years of age (n = 12), as compared to those in the
group who lost ambulation later (n = 11). These results
confirm that the relative number of circulating CD49dhi
T cells can predict disease progression (Fig. 1d). If we
look for the relative numbers of both subpopulations,
we observed that DMD patients with CD49dhiCD4+ ≥
31.91 % and CD49dhiCD8+ T cells ≥ 45.90 % have 100 %
chance to lose ambulation before 10 years of age (sensi-
tivity of 41 %; x2 = 5.85; p = 0.01). This will be very im-
portant when carrying out clinical trials for new drugs in
the future.
Since no statistical difference in levels of circulating
CD49dhi T cells could be observed between ≤1 m/s
ambulating versus non-ambulating patients, we thus
split the patients into two groups (slow progressors:
unable to walk with 10 years or more, and fast pro-
gressors: unable to walk before 10 years) and check
the numbers of CD49dhi T cells just as a function of
disease progression. For the slow progressors, no sig-
nificant difference was found between ≤1 m/s (n = 11)
and non-ambulating (n = 15) patients. For the fast
progressors, we observed higher numbers of CD49dhi
T cells in non-ambulating patients (n = 16) when
compared to ≤1 m/s patients (n = 12) (Additional file
6: Figure S3).
We performed the same analyses in a longitudinal
study, following the same patient over time (≤1 m/s and
unable to walk). Again, we observed higher numbers of
CD49dhiCD4+ T cells when the patient became unable
to walk comparing with ≤1 m/s only in the group of fast
progressors (n = 4) (Additional file 6: Figure S3).
To investigate whether CD49dhi is also a common bio-
marker in patients with inflammatory disorders of the
skeletal muscle, we investigated the relative numbers of
CD49dhi T cells from patients with inclusion body myo-
sitis (IBM), an example of an inflammatory disorder of
the skeletal muscle [20]. It is important to note that no
difference was observed when IBM patients were com-
pared to healthy controls (Table 2), further reinforcing
the role of the relative numbers of CD49dhi T as a bio-
marker for DMD severity in patients with established
genetic diagnosis.
CD49d+-activated T lymphocytes in inflammatory
infiltrates
We investigated CD49d in T cells within the skeletal
muscle of nine DMD patients. Initial analysis showed no
difference in the numbers of CD4+ T cells and a trend to
a higher number of CD8+ T lymphocytes within the in-
flammatory infiltrate (Fig. 2a) in the muscle of rapid-
progressing DMD patients. However, when we applied
HLA-DR immunostaining as a T cell activation marker,
we detected significantly higher numbers of tissue-
resident CD49d+HLA-DR+CD8+ T lymphocytes (but not
CD49d+HLA-DR+CD4+ T cells) in patients who had a
rapid disease progression (Fig. 2b) (p < 0.05).
CD49d-mediated T cell migratory responses correlate
with disease progression
We next investigated the transendothelial migration of
CD49d-positive T cells isolated from the different sub-
groups of DMD patients with different disease severity.
We observed that transendothelial migration of
CD49dhiCD4+ and CD49dhiCD8+ T cells was higher
when isolated from DMD patients than from their
healthy counterparts (p < 0.05 and p < 0.01, respectively).
More importantly, we observed that CD49dhiCD8+ T
cells from wheelchair-bound DMD patients migrated
faster through an endothelial layer than those isolated
from less severe DMD patients, still able to walk faster
than 1 m/s (p < 0.05) (Fig. 3a).
Since CD49d is a fibronectin receptor, we tested if
its increase was functional by investigating whether T
lymphocytes from DMD patients would migrate faster
through a fibronectin lattice. Higher fibronectin-
driven CD4+ T cell migratory responses were posi-
tively correlated with disease progression (p < 0.01)
(Fig. 3b), being statistically significant for
CD49dhiCD4+ and CD49dhiCD8+ T cells (p < 0.001
and p < 0.05, respectively) (Fig. 3b) when compared to
healthy controls.
Table 1 Higher relative numbers of circulating CD4+ and CD8+
T cell subsets expressing high densities of CD49d in patients
with Duchenne muscular dystrophy
T cell
subpopulation
Relative cell number (mean ± SD)a p value
Healthy DMD
CD4+CD49ahi 3.66 ± 2.80 4.34 ± 3.18 0.75
CD8+CD49ahi 3.81 ± 3.25 4.02 ± 3.66 0.93
CD4+CD49dhi 23.25 ± 5.86 29.72 ± 8.66 0.007
CD8+CD49dhi 26.28 ± 5.89 34.66 ± 12.00 0.009
CD4+CD49ehi 34.95 ± 9.28 34.97 ± 7.70 0.87
CD8+CD49ehi 31.10 ± 8.17 34.04 ± 13.42 0.46
CD4+CD49fhi 30.53 ± 7.60 27.85 ± 9.37 0.36
CD8+CD49fhi 18.73 ± 5.37 18.34 ± 7.75 0.65
CD4+CD11ahi 22.71 ± 14.23 19.30 ± 12.80 0.60
CD8+CD11ahi 38.31 ± 11.39 44.64 ± 11.30 0.33
aData are presented as relative cell numbers of T cell subsets expressing high
levels of a given integrin subunit. Numbers in italics illustrate statistically
significant differences between normal subjects and Duchenne muscular
dystrophy (DMD) patients, with corresponding p values




Fig. 1 Higher relative numbers of CD49dhi T cells correlate with rapid disease progression. a CD49d membrane expression in CD4+ and CD8+ T
cell subsets. The values correspond to the percentages of the T cell subpopulation with a high CD49d expression (CD49dhi T). Dashed bars define
high versus low CD49d expression, and the red curves represent isotype-matched antibody. b Relative numbers of CD49dhiCD4+ and CD49dhiCD8
+ T cells in different groups of DMD patients organized according to their disease progression, as well as healthy controls. c Retrospective study
of wheelchair-bound patients organized according to the age when they lost ability to walk. d Prospective study in patients able to walk 1 m/s
or less, organized according to the age when they became wheelchair bound. The number of DMD patients analyzed in each group appears in
parentheses. b *p < 0.05, **p < 0.01, ***p < 0.001
Table 2 No difference was observed in the relative numbers of circulating CD4+ and CD8+ T cell subsets expressing high densities
of CD49d in patients with IBM and healthy controls
T cell
subpopulation
Relative cell number (mean ± SD)a p value Number of individuals
Healthy IBM Healthy IBM
CD4+CD49dhi 35.24 ± 13.10 34.23 ± 18.25 0.44 21 23
CD8+CD49dhi 44.89 ± 14.66 43.92 ± 14.59 0.60 17 20
aData are presented as relative cell numbers of T cell subsets expressing high levels of the CD49d integrin subunit. No significant differences (p > 0.05) were seen
in both T cell subpopulations when healthy patients were compared to IBM individuals
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Considering that integrins are involved in leukocyte
proliferation and survival [12], and that VLA-4 inter-
action with fibronectin induces lymphocyte proliferation,
we evaluated cell proliferation and cell death after the
16-h migration period in the different groups of patients.
No differences were observed (data not shown), indicat-
ing that the increased migratory responses are not re-
lated to increased proliferation or cell survival.
Anti-CD49d mAb blocks transendothelial, fibronectin-
driven migration and myotube adhesion of T cells from
DMD patients
Because the VLA-4/VCAM-1 interaction on the surface
of endothelial cells is important for transmigration of T
cells from the blood, and considering that the VLA-4/fi-
bronectin interaction is important for cell migration
within the tissues, we investigated whether we could ab-
rogate the migration of T cells ex vivo by selectively
blocking CD49d. We pretreated T cells with an anti-
CD49d mAb and compared their migration with that of
T cells treated with an unrelated isotype-matched Ig.
Anti-CD49d pretreatment efficiently and preferentially
blocked transendothelial (p < 0.001) and fibronectin-
driven migration of CD49dhiCD4+ (p < 0.05) and
CD49dhiCD8+ (p < 0.01) T cells isolated from DMD pa-
tients (Fig. 4a, b). Moreover, since DMD-derived
CD49dhiCD4+ (p < 0.001) and CD49dhiCD8+ (p < 0.01) T
cells exhibited a higher adhesion onto monolayers of hu-
man myotubes (Fig. 4c), we tested the effect of blocking
CD49d (Additional file 7: Figure S4a). The anti-CD49
mAb treatment significantly abrogated CD49dhiCD4+
and CD49dhiCD8+ T cell adhesion (p < 0.05 and p < 0.01,
respectively), and in the case of CD8+CD49dhi T cell
subsets, values were similar to those seen when control
Ig was applied on lymphocytes from healthy individuals
(Fig. 4c). Moreover, anti-CD49d pretreatment preferen-
tially blocked the adhesion of CD49dhiCD8+ (p=0.02) T
cells (Additional file 7: Figure S4b). These results pro-
vide a proof of concept to design a therapeutic interven-
tion to minimize the accelerating effect of increased
CD49dhi T cells, and of exacerbated inflammation, on
the progression of the DMD phenotype.
Discussion
We demonstrate that circulating CD49dhi T cells can be
successfully used as a biomarker for disease progression
in DMD patients. Moreover, this seems to be specific for
a
b
Fig. 2 Higher numbers of activated CD8+CD49d+ T cells in muscle of DMD patients with rapid progression. a Number of CD4+ and CD8+
T lymphocytes per inflammatory infiltrate. b Relative number of T cells simultaneously expressing CD49d and the T cell activation marker
HLA-DR. The biopsies were performed at the beginning of the disease, and patients were divided into two groups according to the age
when they became wheelchair bound. The number of DMD patients analyzed in each group appears in parentheses
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DMD since it is not found in IBM patients, who also
suffer from an inflammatory muscle disease.
The percentages of circulating CD49dhiCD4+ and
CD49dhiCD8+ T lymphocytes in DMD subjects corre-
lated with disease prognosis in both ambulant and
non-ambulant patients. Importantly, rapid disease
progression in DMD patients can be predicted by de-
tecting increased numbers of circulating CD49dhiCD4+
and CD49dhiCD8+ T lymphocytes at the beginning of
the disease. This is also in agreement with our previous
report, showing that decreased stride frequency and
increased CD49dhiCD4+T lymphocytes are predictive
markers of clinical outcome in the GRMD dog model of
DMD [21]. Therefore, we propose that for the fast
progressors, CD49d can be a biomarker for the prognosis
and also for disease severity, since the frequencies of
CD49dhi T cells increase progressively once the patient be-
gins to walk in 1 m/s or less. This fits with the hypothesis
that CD49d can be involved in the pathogenesis of the
muscular lesions.
Corticotherapy is widely used to improve DMD
phenotype, and the chronic use of corticotherapy could
modify the percentages of the CD49dhi T cells. However,
this is not the case since the patients who were no lon-
ger able to walk had stopped steroid treatment before
the analyses, and the changes in CD49d expression per-
sisted. In addition, it has been reported that glucocorti-
coids do not modulate in vitro or in vivo CD49d
expression [22, 23]. Furthermore, all patients who were
still able to walk were all under steroid treatment, thus
excluding steroid treatment as a putative confounder.
Yet, one can argue that good responders to glucocorti-
coids have a lower degree of inflammation and, as a con-
sequence, lower levels of CD49dhi T cells. When we
followed the same patient at two different time points of
disease (≤1 m/s: all under with corticotherapy, and un-
able to walk: with no longer corticosteroid treatment),
we clearly found that the frequency of CD49dhiCD4+ T
cells increased along with progression of severity only in
the fast progressors. Considering that both groups (fast
and slow progressors) were under the same conditions
regarding corticotherapy, it suggests that the frequency
of CD49dhiCD4+ T cells is not influenced by this drug.
This individual follow-up with a small number of pa-
tients is supported by the same analysis in a transversal
study with a larger cohort (Additional file 6: Figure S3a,
(a)
(b)
Fig. 3 Enhanced migratory response of T lymphocytes from DMD patients correlates with disease severity. a Migration of T lymphocytes through
endothelial cells. b Fibronectin-driven migration. Relative numbers of CD49dhiCD4+ and CD49dhiCD8+ migrating cells in healthy controls and in
the different groups of DMD patients, subdivided according to their ability to walk. The number of DMD patients analyzed in each group appears
in parentheses. *p < 0.05, **p < 0.01, ***p < 0.001
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b, e, f ). CD49d can thus be used for clinical trials to
stratify DMD patients into predictive slow and rapid
progressors, whether these patients are under steroid
treatment or not.
Using the T cell activation marker HLA-DR, we found
a positive correlation with the relative number of
CD49dhiHLA-DR+CD8+ T lymphocytes in the blood of
patients who became wheelchair bound before 10 years
of age. We also found more activated CD49d+HLA-
DR+CD8+ T cells in the muscle of rapid progressors.
Together, these findings support the concept that this
subpopulation plays an important role in the pathogen-
esis of DMD and that the higher the relative number of
CD49dhi T cells in the blood, the more rapid is the dis-
ease progression.
More importantly, we show that both transendothelial
and fibronectin-driven migration of CD49dhi T cells
from DMD patients were enhanced, as well as the bind-
ing of CD49dhi T lymphocytes to myotubes. Considering
that there was a correlation between the highest num-
bers of CD49dhi T cells, the poor prognosis and disease
severity, the highest migration, and the already known
function of CD49d in the interaction with endothelium
and fibronectin, we propose as an hypothesis that
CD49d may facilitate T cell migration into muscle tissue.
This suggests that CD49d acts by accelerating the migra-
tion of the T cells into the muscle, consequently enhan-
cing inflammatory infiltrate in dystrophic muscle and
directly targeting muscle fibers. Pretreatment of DMD T
cells with an anti-CD49d mAb prevented transendothe-
lial migration and decreased the ability of these cells to
attach to myotubes. These findings strongly suggest that
treatment with an anti-CD49d mAb may decrease in
vivo the transendothelial migration of the T cells, impair
their interaction with fibronectin within skeletal muscle,
and abrogate cell-cell adhesive interactions with muscle
fibers to slow down eventual necrosis.
It is important to mention that the pretreatment
with anti-CD49d decreased the transendothelial and
fibronectin-driven migration of CD49dhi T cells but
increased migration of CD49dlow T lymphocytes. In
principle, cells with low expression of CD49d repre-
sent T cells that are not activated. In this regard, the
influx into the muscle would not be a problem since
non-activated cells would recirculate. In a second
vein, CD49dlowCD4+ T lymphocytes may correspond
a b
c
Fig. 4 Ex vivo anti-CD49d antibody treatment preferentially blocks migratory responses of DMD-derived CD49dhi T cells. Blocking effects of the
anti-CD49d mAb upon transendothelial (a) and fibronectin-driven migration (b) of CD49dlowCD4+ or CD49dhiCD4+ and CD49dlowCD8+ or
CD49dhiCD8+ T cells from DMD patients. Control Ig-treated cells were taken as 100 % of migratory/adhesive responses. c Adhesion onto
myotubes of CD49dhiCD4+ and CD49dhiCD8+ T cells from DMD patients and healthy controls following treatment with anti-CD49d mAb or
control Ig. *p < 0.05, **p < 0.01, ***p < 0.001
Pinto-Mariz et al. Skeletal Muscle  (2015) 5:45 Page 8 of 10
to regulatory T cells. If this is the case, they will ra-
ther have a protective anti-inflammatory role upon
the entrance of activated CD49dhiHLA-DR+CD4+ T
lymphocytes. Of note, we did not observe the same
kind of event when lymphocytes were led to adhere
onto myotubes. In those sets of experiments, no en-
hancement in the adhesion was observed regarding
the CD49dlow T cells. Actually, a blockade of both
low and high subpopulations seemed to occur after
the pretreatment in vitro, being however more im-
portant in CD49dhi T cells when compared to the
corresponding low subpopulation. No difference was
observed between low and high CD4+ T cells. Yet,
considering the short number of patients studied,
more experiments should be done to clarify this
point.
The anti-CD49d mAb Natalizumab has already
been used to treat multiple sclerosis and inflamma-
tory bowel disease [24] and has proved to be benefi-
cial for several thousands of patients [25–27], even
though progressive multifocal leukoencephalopathy
was reported in 0.08–0.03 % of patients treated for at
least 24 months. Natalizumab has been well tolerated
by children suffering from multiple sclerosis, resulting
in clinical benefits [28]. Since DMD patients have
high numbers of circulating CD49dhi T cells as well
as of CD49d+ T cells within the muscle, the thera-
peutic targeting of CD49d could be beneficial, and
clinical trials should be envisaged to confirm this
effect.
Conclusions
We propose that CD49d can be used as a novel prog-
nostic biomarker to stratify DMD patients into homo-
geneous cohorts in future clinical trials, improving
potentially the significance of these costly studies. In-
hibition of CD49d-mediated interactions could be
envisioned as a novel therapeutic strategy for improv-
ing disease progression in DMD patients, by decreas-
ing the immune response, in conjunction with other
gene therapy approaches such as exon skipping or
gene replacement, which in some cases triggers
dystrophin-specific immune response [29–31].
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